Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CGS 15943 is an orally bioavailable non-xanthine antagonist of Adenosine Receptor. In transfected CHO cells, its Ki for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM , respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 91.00 | |
10 mg | In stock | $ 133.00 | |
25 mg | In stock | $ 223.00 | |
50 mg | In stock | $ 333.00 | |
100 mg | In stock | $ 498.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 93.00 |
Description | CGS 15943 is an orally bioavailable non-xanthine antagonist of Adenosine Receptor. In transfected CHO cells, its Ki for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM , respectively. |
Targets&IC50 | A1 receptor:3.5 nM (ki), A2A receptor:4.2 nM (ki), p110γ:1.1 μM, A2B receptor:16 nM (ki), p110δ:8.47 μM, A3 receptor:51 nM (ki) |
In vitro | CGS 15943 inhibits the kinase activity of the class IB PI3K isoform p110γ (IC50: 1.1 μM). CGS 15943 shows slight inhibition on p110δ (IC50: 8.47 μM). CGS 15943 (0-20 μM; 24 hours) reduces the phosphorylation of Akt at its residues Ser473 and Thr308 in HLF and Sk-Hep-1 cells. CGS 15943 (0-20 μM; 72 hours) inhibits growth of HLF and SK-Hep-1 cells, as well as HepG2 and PLC-PRF-5 cells[3]. |
Molecular Weight | 285.69 |
Formula | C13H8ClN5O |
CAS No. | 104615-18-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 12.22 mg/mL (42.77 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CGS 15943 104615-18-1 GPCR/G Protein Neuroscience PI3K/Akt/mTOR signaling PI3K Adenosine Receptor Phosphoinositide 3-kinase P1 receptor CGS15943 inhibit CGS-15943 Inhibitor inhibitor